Japan Lifeline to buy US transseptal device maker Cross Vascular for up to USD 4,734,000

By Public Technologies
  • Japan Lifeline agreed to buy Cross Vascular, via wholly owned subsidiary JLL Med USA, making it an indirect wholly owned unit.
  • Deal values Cross Vascular common shares at USD 4,734,000, including USD 734,000 at closing and up to USD 4,000,000 earn-out.
  • Advisory fees and related costs estimated at JPY 234 million, taking total estimated outlay to about JPY 977 million.
  • Signing and closing are scheduled for Sept. 30, 2026.
  • JLL Med USA will inject USD 7,265,000 into Cross Vascular, lifting capital to USD 7,274,000 for debt payments, working capital.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. JLL - Japan Lifeline Co. Ltd. published the original content used to generate this news brief on September 29, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.
The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.
To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.
 

Cryptocurrency-related content is intended solely as news and market commentary. Crypto Derivatives are not available to Retail clients registered with Capital Com (UK) Ltd.